Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes

Oncotarget

Volumn 3, Issue 8, 2012, Pages 843-853

  Feichtinger, Julia ^a   Aldeailej, Ibrahim ^a   Anderson, Rebecca ^a   Almutairi, Mikhlid ^a   Almatrafi, Ahmed ^a   Alsiwiehri, Naif ^a   Griffiths, Keith ^b   Stuart, Nicholas ^a,c,e   Wakeman, Jane A ^a   Larcombe, Lee ^d   McFarlane, Ramsay J ^a,e  

^a BANGOR UNIVERSITY   (United Kingdom)

^b BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^c BANGOR UNIVERSITY   (United Kingdom)

^d CRANFIELD UNIVERSITY   (United Kingdom)

^e NISCHR Cancer Genetics Biomedical Research Unit   (United Kingdom)

Author keywords

Cancer biomarkers; Cancer testes antigens; Cohesins drug targets; Meiosis; Oncogenes; Prdm9

Indexed keywords

SPO11 PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HORMAD1 GENE; HUMAN; HUMAN CELL; MALE; MEIOSIS; MOUSE; NONHUMAN; NUCLEAR PROTEIN IN TESTIS GENE; ONCOGENE; PRDM9 GENE; RAD21L GENE; REC8 GENE; REGULATOR GENE; SMC1 BETA GENE; SPO11 GENE; STAG3 GENE; STRA8 GENE; SYCE1 GENE; SYCP1 GENE; TESTIS SPECIFIC SERINE THREONINE KINASE 1 GENE; TEX19 GENE; TUMOR GENE; UPREGULATION;

EID: 84868617843     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.580     Document Type: Article

References (50)

1. Jensen-Jarolim E, Singer J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines. 2011; 10: 1281-1289.
2. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011; 239: 27-44.
3. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy- revisited. Nat Rev Drug Discov. 2011; 10: 591-600.
4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480: 480-489.
5. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol. 2011; 186: 1325-1331.
6. Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future optimism with immunomodulation therapy. Cancer J. 2011; 17: 372-378.
7. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol. 2011; 8: 577-585.
8. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J ClinOncol. 2011; 29: 4828-4836.
9. Tuma RS. Enthusiasm for antibody-drug conjugates. J Natl Cancer Inst. 2011; 103: 1493-1494.
10. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012; 148: 1081-1084.
11. Straten P, Andersen MH. The anti-apoptotic members of the Bcl-2 family are attractive tumour associated antigens. Oncotarget 2010; 1: 239-245.
12. Scrimieri F, Calhoun ES, Patel K, Gupta R, Huso RH, Kern SE. FAM190A rearrangements provide a multitude of individualized tumour signatures and neo-antigens in cancer. Oncotarget 2011; 2: 69-75.
13. Ionov Y. A high throughput method for identifying personalized tumour-associated antigens. Oncotarget 2010; 1: 148-155.
14. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells. 2007; 25: 707-711.
15. Almeida LG, Sakabe NJ, de Oliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJ, et al. CT database: a knowledge-base of high throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 2009; 37: D816-819.
16. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009; 100: 2014-2021.
17. Cheng YH, Wong EW, Cheng CY. Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis. 2011; 1: 209-220.
18. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Marie Nicolay HJ, Sigalotti L, Maio M. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011; 5: 164-182.
19. Mirandola L, Cannon M, Cobos E, Bernardini G, Jenkins MR, Kast WM, Chiriva-Internati M. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol. 2011; 30: 127-137.
20. Lim SH, Zhang Y, Zhang J. Cancer-testis antigens: the current status on antigen regulation and potential clinical use. Am J Blood Res. 2012; 2: 29-35.
21. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5: 615-625.
22. Fijak M, Meinhardt A. The testis in immune privilege. Immunol Rev. 2006; 213: 66-81.
23. Mruk DD, Cheng CY. Tight junctions in the testis: new perspectives. Philos Trans R Soc Lon B Sci. 2010; 365: 1621-1635.
24. Hunder NN, Wallen H, Cao J, HendricksDW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Eng J Med. 2008; 358: 2698-2703.
25. Hofmann O, Cabellero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA. 2008; 105: 20422-20427.
26. Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausberg RL, Jongeneel CV, Old LJ, Simpson AJ. Identification of cancer/testis-antigen genes by massive parallel signature sequencing. Proc Natl Acad Sci USA. 2005; 102: 7940-7945.
27. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001; 61: 5544-5551.
28. Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ, Neville AM. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA. 2009; 106: 13493-13498.
29. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C. MAGE-A tumour antigens target p53 transactivation function through histone deacetylase recruitement and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA. 2006; 103: 11160-11165.
30. Duan Z, Duan Y, Lamendola DE, Yusurf RZ, Naeem R, Penson RT, Seiden MV. Over expression of MAGE/ GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 2003; 9: 2778-2785.
31. Chalmel F, Lardenois A, Primig M. Toward understanding the core meiotic transcriptome in mammals and its implications for somatic cancer. Ann N Y Acad Sci. 2007; 1120: 1-15.
32. Wang J, Emadali A, Le Bescont A, Callanan M, Rousseaux S, Khochbin S. Induced malignant genome reprogramming in somatic cells by testis-specific factors. Biochim Biophys Acta. 2011; 1809: 221-225.
33. Yanowitz J. Meiosis: making a break for it. Curr Opin Cell Biol. 2010; 22: 744-751.
34. Zickler D, Kleckner N. Meiotic chromosomes: integrating structure and function.AnnuRev Genet. 1999; 33: 603-754.
35. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells.Nature. 2011; 474: 212-215.
36. Turner JM. Meiotic sex chromosome inactivation. Development. 2007; 134: 1823-1831.
37. Jessberger R. Cohesin complexes get more complex: the novel kleisin RAD21L. Cell Cycle. 2011; 10: 2053-2054.
38. Uhlmann F. Cohesin subunit Rad21L, the new kid on the block has new ideas. EMBO Rep. 2011; 12: 183-184.
39. Ishiguro K, Kim J, Fujiyama-Nakamura S, Kato S, Watanabe Y. A new meiosis-specific cohesion complex implicated in the cohesion code for homologous pairing. EMBO Rep. 2011; 12: 267-275.
40. Lee J, Hirano T. RAD21L, a novel cohesion subunit implicated in linking homologous chromosomes in mammalian meiosis. J Cell Biol. 2011; 192: 263-276.
41. Noguchi T, Kato T, Wang L, Maeda Y, Ikeda H, Sato E, Knuth A, Gnjatic S, Ritter G, Sakaquchi S, Old LJ, Shiku H, Nishikawa H. Intracellular tumour-associated antigens represent effective targets for passive immunotherapy. Cancer Res. 2012; 72: 1672-1682.
42. Guo K, Tang JP, Tan CPB, Hong CW, Al-Aidaroos AQO, Varghese L, Huang C, Zeng Q. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med. 2011; 3: ra85.
43. Chalmel F, Rolland AD, Niederhauser-Wiederkehr C, Chung SS, Demougin P, Gattiker A, Moore J, Patard JJ, Wolgemuth DJ, Jéqou B, Primig M. The conserved transcriptome in human and rodent male gametogenesis. Proc Natl Acad Sci USA. 2007; 104: 8346-8351.
44. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffmann EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA. 2007; 104: 12837-12842.
45. Janic A, Mendizabal L, Llamazares S, Rossell D, Gonzalez C. Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Nature. 2010; 330: 1824-1827.
46. Hochwagen A, Marais GA. Meiosis: a PRDM9 guide to the hotspot of recombination. Curr Biol. 2010; 20: R271-R274.
47. McVean G, Myers S. PRDM9 marks the spot. Nat Genet. 2010; 42: 821-822.
48. Hayashi K, Yoshida K, Matsui Y. A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. Nature. 2005; 438: 374-378.
49. Harigaya Y, Tanaka H, Yamanaka S, Tanaka K, Watanabe Y, Tsutsumi C, Chikashige Y, Hiraoka Y, Yamashita A, Tamamoto M. Selective elimination of messenger RNA prevents an incidence of untimely meiosis. Nature. 2006; 442: 45-50.
50. Hiriart E, Vavasseur A, Touat-Todeschini L, Yamashita A., Gilquin B, Lambert E, Perot J, Shichino Y, Nazaret N, Boyault C, Lachuer J, Perazza D, Yamamoto M, Verdel A. MmiRNA surveillance machinery directs RNAi complex RITS to specific meiotic genes in fission yeast. EMBO J. 2012; 31: 2296-2308.